TY - JOUR
T1 - Quantitative structure-activity relationships
T2 - Analysis of interactions of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2-substituted analogues with rat, mouse, guinea pig, and hamster cytosolic receptor
AU - Romkes, M.
AU - Piskorska-Pliszczynska, J.
AU - Keys, B.
AU - Safe, S.
AU - Fujita, T.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1987
Y1 - 1987
N2 - The competitive receptor binding affinities of thirteen 2-substituted 3,7,8-trichlorodibenzo-p-dioxins to hepatic cytosol from rat, mouse, guinea pig, and hamster were determined with [3H]-2,3,7,8-tetrachlorodibenzo-p-dioxin as the radioligand. Multiple parameter linear regression analysis of the binding data from the four species gave the following equations: pEC50 (rat) = 7.196 + 0.600 π - 0.255 ΔE(s) - 1.683 HB, pEC50 (mouse) = 6.365 + 1.641 π + 1.206 σ°, pEC50 (hamster) = 7.416 + 1.026 π + 0.509ΔE(s) + 0.748 σ°, pEC50 (guinea pig) = 6.892 + 1.035 π where π, ΔE(s), HB, σ°, and V(w) are physicochemical parameters for substitutent lipophilicity, steric effect, hydrogen bonding capacity, electronegativity, and van der Waals volume (relative to H), respectively. These equations demonstrate that there are important species differences in the receptor protein binding site interactions with the substituted analogues. These data, coupled with the known species differences in the molecular properties of the receptor proteins, are evidence for a heterologous nature of the receptor between mammalian species. Multiple parameter linear regression analysis of the relative aryl hydrocarbon hydroxylase (AHH) induction potencies of these analogues in rat hepatoma H-4-II E-cells in culture gave the following equation. The correlation pEC50 (AHH induction) = 3.208 = 0.950 pEC50 (rat binding) - 0.955 ΔB5 between receptor binding and AHH induction was dependent on a steric parameter (ΔB5, STERIMOL) and the results suggest that an additional substituent-dependent process (e.g., an activation step) may be required after initial ligand-receptor binding for the ultimate expression of the receptor-mediated response (i.e., AHH induction).
AB - The competitive receptor binding affinities of thirteen 2-substituted 3,7,8-trichlorodibenzo-p-dioxins to hepatic cytosol from rat, mouse, guinea pig, and hamster were determined with [3H]-2,3,7,8-tetrachlorodibenzo-p-dioxin as the radioligand. Multiple parameter linear regression analysis of the binding data from the four species gave the following equations: pEC50 (rat) = 7.196 + 0.600 π - 0.255 ΔE(s) - 1.683 HB, pEC50 (mouse) = 6.365 + 1.641 π + 1.206 σ°, pEC50 (hamster) = 7.416 + 1.026 π + 0.509ΔE(s) + 0.748 σ°, pEC50 (guinea pig) = 6.892 + 1.035 π where π, ΔE(s), HB, σ°, and V(w) are physicochemical parameters for substitutent lipophilicity, steric effect, hydrogen bonding capacity, electronegativity, and van der Waals volume (relative to H), respectively. These equations demonstrate that there are important species differences in the receptor protein binding site interactions with the substituted analogues. These data, coupled with the known species differences in the molecular properties of the receptor proteins, are evidence for a heterologous nature of the receptor between mammalian species. Multiple parameter linear regression analysis of the relative aryl hydrocarbon hydroxylase (AHH) induction potencies of these analogues in rat hepatoma H-4-II E-cells in culture gave the following equation. The correlation pEC50 (AHH induction) = 3.208 = 0.950 pEC50 (rat binding) - 0.955 ΔB5 between receptor binding and AHH induction was dependent on a steric parameter (ΔB5, STERIMOL) and the results suggest that an additional substituent-dependent process (e.g., an activation step) may be required after initial ligand-receptor binding for the ultimate expression of the receptor-mediated response (i.e., AHH induction).
UR - http://www.scopus.com/inward/record.url?scp=0023232569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023232569&partnerID=8YFLogxK
M3 - Article
C2 - 3040239
AN - SCOPUS:0023232569
SN - 0008-5472
VL - 47
SP - 5108
EP - 5111
JO - Cancer research
JF - Cancer research
IS - 19
ER -